What is Cns Pharmaceuticals Inc Annual Net Profit?

Cns Pharmaceuticals Inc Annual Net Profit fell 23.42% in the last year to $18.85 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

What is Cns Pharmaceuticals Inc Price to Earning Ratio?

Cns Pharmaceuticals Inc Price to Earning Ratio is -0.33, which is negative.

What is Cns Pharmaceuticals Inc Stock Price?

Cns Pharmaceuticals Inc Stock Price fell 99.58% and underperformed its sector by 108.65% in the past year.

What is Cns Pharmaceuticals Inc Quarterly Net profit?

Cns Pharmaceuticals Inc Quarterly Net profit fell 23.95% YoY to $5.61 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

What is Cns Pharmaceuticals Inc Return on Equity(ROE)?

Cns Pharmaceuticals Inc Return on Equity(ROE) for the last financial year was -1,018.78%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Cns Pharmaceuticals Inc Mutual Fund Holding?

Cns Pharmaceuticals Inc Mutual Fund Holding increased by 25.11% in the last quarter to 26.03.

What is Cns Pharmaceuticals Inc Promoter Share Holding?

Cns Pharmaceuticals Inc Promoter Share Holding stayed the same in the most recent quarter at 2.47%.

What is Cns Pharmaceuticals Inc Interest Coverage Ratio?

Cns Pharmaceuticals Inc Interest Coverage Ratio is -1364.54, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Cns Pharmaceuticals Inc Institutional Holding?

Cns Pharmaceuticals Inc Institutional Holding increased by 178.32% in the last quarter to 179.32.

How is the Cns Pharmaceuticals Inc today?

The Cns Pharmaceuticals Inc today is trading in the green, up by 2.49% at 3.71.

How has Cns Pharmaceuticals Inc performed historically?

The Cns Pharmaceuticals Inc is currently trading up 2.49% on an intraday basis in the past week the index rose 18.91%. The index has been down -31.30% in the past quarter and fell -99.58% in the past year. You can view this in the overview section.

Cns Pharmaceuticals Inc XNAS: CNSP

Cns Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Name: Cns Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Cns Pharmaceuticals Inc
Rating: 0.80600
Author: Trendlyne DVM scores

Download real time

3.71 0.09 (2.49%)

99.62% Fall from 52W High

106.1K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Cns Pharmaceuticals Inc is on 01 Apr 2025 for the purpose of CNS Pharmaceuticals Inc Fourth Quarter Earnings Results for 2024 See details

Cns Pharmaceuticals Inc Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	5.6
PE TTM Negative PE TTM Unavailable in chosen country	-0.3
Price to Book Below industry Median Unavailable in chosen country	1.7
Institutional holding current Qtr % Market Leader Unavailable in chosen country	179.3
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-23.9
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	8.4
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-39.9
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-1,018.8
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-255.5

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

8.5 / 100

Technically Bearish

23.7 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Cns Pharmaceuticals Inc Stock Price Analysis

Day Price Range 2.5% 1 Day return Unavailable in chosen country	3.7 (LTP) 3.43.8 LowHigh
Week Price Range 18.9% 1 Week return Unavailable in chosen country	3.7 (LTP) 34.6 LowHigh
Month Price Range 14.9% 1 Month return Unavailable in chosen country	3.7 (LTP) 24.6 LowHigh
52 Week Price Range -99.6% 1 Year return Unavailable in chosen country	3.7 (LTP) 2975 LowHigh

View full Share Price History

Cns Pharmaceuticals Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Cns Pharmaceuticals Inc Stock Analysis

Cns Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Cns Pharmaceuticals Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$18.85 M	23.42%	negative	Annual Net Profit fell 23.42% in the last year to $18.85 M. Its sector's average net profit growth for the last fiscal year was -32.43%.
Price to Earning Ratio	-0.33	-	negative	Price to Earning Ratio is -0.33, which is negative.
Stock Price	$3.71	-99.58%	negative	Stock Price fell 99.58% and underperformed its sector by 108.65% in the past year.
Quarterly Net profit	$5.61 M	23.95%	negative	Quarterly Net profit fell 23.95% YoY to $5.61 M. Its sector's average net profit growth YoY for the quarter was -47.3%.
Return on Equity(ROE)	-1018.78 %	-1018.78%	negative	Return on Equity(ROE) for the last financial year was -1,018.78%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	26.03 %	25.11%	positive	Mutual Fund Holding increased by 25.11% in the last quarter to 26.03.
Promoter Share Holding	2.47 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 2.47%.
Interest Coverage Ratio	-1364.54	-	negative	Interest Coverage Ratio is -1364.54, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	179.32 %	178.32%	positive	Institutional Holding increased by 178.32% in the last quarter to 179.32.

VIEW LESS

Loading data..

Cns Pharmaceuticals Inc - Company Profile

What does Cns Pharmaceuticals Inc do?

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Cns Pharmaceuticals Inc Management structure

All Gross Remunerations are in USD

Mr. John M. Climaco

President, Chief Executive Officer and Director

624.35 K

2023

Gross Remuneration

Year

Mr. Christopher Downs

Chief Financial Officer and Principal Accounting Officer

401.52 K

2023

Gross Remuneration

Year

Dr. Sandra L. Silberman, PhD

Chief Medical Officer

270.15 K

2023

Gross Remuneration

Year

Cns Pharmaceuticals Inc Board of directors

All Gross Remunerations are in USD

Mr. Andrzej Andraczke

Independent Director

2024

Gross Remuneration

Year

Ms. Amy Mahery

Independent Director

2024

Gross Remuneration

Year

Cns Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

99.62% Fall from 52W High

Cns Pharmaceuticals Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Cns Pharmaceuticals Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Cns Pharmaceuticals Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Cns Pharmaceuticals Inc Stock Analysis

Cns Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 23.42% in the last year to $18.85 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio is -0.33, which is negative.

Stock Price fell 99.58% and underperformed its sector by 108.65% in the past year.

Quarterly Net profit fell 23.95% YoY to $5.61 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Return on Equity(ROE) for the last financial year was -1,018.78%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 25.11% in the last quarter to 26.03.

Promoter Share Holding stayed the same in the most recent quarter at 2.47%.

Interest Coverage Ratio is -1364.54, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 178.32% in the last quarter to 179.32.

Cns Pharmaceuticals Inc - Company Profile

What does Cns Pharmaceuticals Inc do?

Cns Pharmaceuticals Inc Management structure

Mr. John M. Climaco

President, Chief Executive Officer and Director

Mr. Christopher Downs

Chief Financial Officer and Principal Accounting Officer

Dr. Sandra L. Silberman, PhD

Chief Medical Officer

Cns Pharmaceuticals Inc Board of directors

Mr. Andrzej Andraczke

Independent Director

Ms. Amy Mahery

Independent Director

Cns Pharmaceuticals Inc FAQ

How is Cns Pharmaceuticals Inc today?

Cns Pharmaceuticals Inc today is trading in the green, and is up by 2.49% at 3.71.

How has Cns Pharmaceuticals Inc performed historically?

Cns Pharmaceuticals Inc is currently trading up 2.49% on an intraday basis. In the past week the stock rose 18.91%. stock has been down -31.30% in the past quarter and fell -99.58% in the past year. You can view this in the overview section.